BioWorld

Dec. 5, 2006

View Archived Issues

Onyx's Shares Drop On Top-Line Results Of Nexavar In Melanoma

A Phase III failure of Nexavar in advanced melanoma thumped Onyx Pharmaceuticals Inc.'s stock by more than 30 percent Monday. (BioWorld Today) Read More

Pfizer's Torcetrapib Failure Boosts Isis Market Chances

Read More

FM-VP4 Misses Main Endpoint; Forbes MediTech Falls By Half

Read More

Sangamo Gets VEGF-ZFP Rights From Edwards In Angiogenesis

Read More

Micromet Shares Take Ride On $10M Serono Payment

Read More

Other News To Note

Read More

Clinic Roundup

Read More